About Cugene
Cugene is a company based in Waltham (United States) founded in 2016. It operates as a B2B. Cugene offers products and services including CUG252, TILKine, and VitoKine. Cugene operates in a competitive market with competitors including BeiGene, Moderna, Forge Biologics, Incyte and ALX Oncology, among others.
- Headquarter Waltham, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cugene.com
- Legal Name Cugene, Inc.
Products & Services of Cugene
Cugene offers a comprehensive portfolio of products and services, including CUG252, TILKine, and VitoKine.
Engineered IL-2 for expanding regulatory T cells in autoimmune diseases.
Bispecific system targeting tumor lymphocytes for cancer treatment.
Engineered IL-2 delivery for enhancing cytotoxic activity in tumors.
People of Cugene
2 people are tracked at Cugene (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Luke Li | CEO | Leadership |
Lida L. | Office Manager | Team |
Complete people profiles for Cugene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Cugene
Cugene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Forge Biologics, Incyte and ALX Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. |
Detailed competitors of Cugene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cugene
The website of Cugene (cugene.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 80% vs previous month
Websites whose visitors overlap most with Cugene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hcbioscience.com | 100% | – | – | View details | |
| marengotx.com | 99% | 3.3K | #5,030,761 | View details | |
| oxeiabiopharma.com | 99% | 3.3K | #5,389,668 | View details | |
| octagontherapeutics.com | 89% | 2K | #8,651,290 | View details | |
| vedantabio.com | 28% | 5.6K | #3,168,764 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Cugene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cugene
Complete news archive for Cugene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cugene
10 companies that operate in the same segment as Cugene (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cugene
Cugene was founded in 2016.
Cugene is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Cugene is a biotechnology company based in the United States, focusing on precision protein engineering to create biologics for treating cancer and autoimmune diseases. They utilize expertise in immunology and oncology to develop therapies like CUG252, which targets regulatory T cells, and technologies such as TILKine for tumor treatment. The company operates from Waltham, Massachusetts, aiming to restore immune homeostasis through innovative drug discovery and partnerships in the biopharmaceutical industry.
Cugene's top competitors include Moderna, BeiGene and Forge Biologics.
Cugene offers CUG252, TILKine, and VitoKine.
Cugene operates through Cugene, Inc..